Skip to main content
. 2022 Nov 13;19(2):139–157. doi: 10.1007/s12519-022-00625-2

Table 2.

Practices based on income status groups of the respondent units

Practices Low and LMIC (175/842, 21%) UMIC
(275/842, 33%)
HIC
(392/842, 47%)
Level of association, P
Local skin care guideline available (n = 799) 100/167 (60) 190/260 (73) 284/372 (76)  < 0.001
Local skin antisepsis guideline available (n = 805) 99/170 (58) 195/260 (75) 306/375 (82)  < 0.001
Skin cleansing solution prior to sterile procedures (n = 842)a n = 175 n = 275 n = 392  < 0.001
 Aqueous chlorhexidine solution 50 (29) 93 (34) 211 (54)
 Combination alcohol and antiseptic 106 (61) 72 (26) 107 (27)
 Iodine-based solution 72 (41) 146 (53) 93 (24)
 Hexachlorophene 2 (1) 3 (1) 8 (2)
 Sterile water 12 (7) 28 (10) 50 (13)
Skin cleansing solution prior to clean procedures (n = 828)a n = 172 n = 271 n = 385  < 0.001
 Aqueous chlorhexidine solution 15 (9) 44 (16) 106 (28)
 Combination alcohol and antiseptic 129 (75) 172 (63) 180 (47)
 Iodine-based solution 10 (6) 34 (13) 9 (2)
 Hexachlorophene 1 (1) 2 (1) 3 (1)
 Sterile water 7 (4) 4 (1) 16 (4)
 Othersb 10 (6) 15 (6) 71 (18)
Differing skin antisepsis for infants ≤ 25 wk GA (n = 833)c 24/172 (14) 60/273 (22) 119/388 (31)  < 0.001
Skin integrity assessment tool (n = 842)a n = 175 n = 275 n = 392  < 0.001
 Braden Q 6 (3) 70 (25) 39 (10)
 Neonatal skin risk assessment tool 66 (38) 57 (21) 61 (16)
 Neonatal skin condition score 26 (15) 55 (20) 56 (14)
 Starkid skin scale 1 (1) 5 (2) 1 (-)
 Neonatal skin risk assessment scale 12 (7) 65 (24) 34 (9)
 Glamorgan pressure injury risk assessment 0 (0) 9 (3) 12 (3)
 Other local toolsd 4 (2) 9 (3) 49 (13)
 None 40 (23) 32 (12) 74 (19)
Umbilical cord care practices (n = 842)a n = 175 n = 275 n = 392  < 0.001
 Leave alone 105 (60) 162 (59) 283 (72)
 Sterile water 46 (26) 33 (12) 50 (13)
 A drying agent 20 (11) 57 (21) 25 (6)
 Topical antibiotic agent 8 (5) 25 (9) 11 (3)
 Topical antifungal agent 2 (1) 5 (2) 1 (-)
 Topical breast milk 2 (1) 7 (3) 0 (0)
 Otherse 16 (9) 29 (11) 44 (11)
Routine use of topical emollients (n = 805), of these 41 (5%) were used for specific GA infants 96/167 (57) 135/258 (52) 104/380 (27)  < 0.001
Frequency of emollient use (n = 334) n = 95 n = 136 n = 103     0.004
 Once daily 37 (39) 63 (46) 38 (37)
 Twice daily 41 (43) 29 (21) 32 (31)
 More than twice daily 13 (14) 31 (23) 17 (16)
 Others 4 (4) 13 (10) 16 (16)
Type of topical emollient useda (n = 842), not just prophylactic n = 175 n = 275 n = 392  < 0.001
 Oil-based 99 (57) 123 (45) 95 (24)
 Petrolatum-based 27 (15) 70 (25) 59 (15)
 Othersf 6 (3) 32 (12) 52 (13)
Issues (often, almost always and always) from any use of emollientsa
 Interference with other adhesives (n = 469) 27/110 (25) 47/178 (26) 39/181 (22)     0.550
 Increased incidence of CONS infection (n = 471) 4/109 (4) 8/179 (4) 7/183 (4)     0.930
 Hyperthermia (n = 465) 4/110 (4) 11/176 (6) 3/179 (2)     0.080
 Tissue burns (n = 463) 6/110 (5) 5/176 (3) 4/177 (2)     0.300
 Environmental contamination causing invasive sepsis (n = 463) 9/109 (8) 11/176 (6) 3/178 (2)     0.020
MARSI prevention
 Tapes for securing tubes (n = 848)a n = 175 n = 275 n = 392     0.001
  Transparent film dressing 70 (40) 116 (42) 131 (33)
  Hydrocolloid base with transparent film or adhesive tape 30 (17) 98 (36) 154 (39)
  Silicone tape 32 (18) 39 (14) 68 (17)
  Plastic polymer skin barrier film 9 (5) 34 (12) 29 (7)
  Zinc oxide adhesive 26 (15) 16 (6) 16 (4)
  Plastic perforated tape 10 (6) 26 (10) 39 (10)
  Hydrogel adhesive 8 (5) 25 (9) 49 (13)
  Othersg 27 (15) 54 (20) 94 (24)
 Use of barrier film underneath the adhesive for skin protection (n = 787) 69/162 (43) 132/254 (52) 220/371 (59)     0.002
 Use of adhesive remover when removing tapes (n = 787) 56/162 (35) 170/257 (66) 298/368 (81)  < 0.001
 Type of adhesive remover used (n = 524 as 4 did not identify their country)a n = 56 n = 170 n = 298  < 0.001
  Alcohol/organic-based products 31 (55) 58 (34) 55 (19)
  Oil-based solvents 22 (39) 80 (47) 92 (31)
  Silicone-based removers 3 (5) 45 (27) 96 (32)
  Othersh 5 (9) 17 (10) 56 (19)
 Additional strategy for MARSI prevention (n = 842)a n = 175 n = 275 n = 392  < 0.001
  Remove adhesive slowly and carefully using moistened gauze/pad 121 (69) 212 (77) 312 (80)
  Pull adhesive tape in a horizontal plane 55 (31) 114 (42) 144 (37)
  Fold the tape back onto itself while continuously wetting the adhesive-skin interface 56 (32) 138 (50) 177 (45)
  Othersi 4 (2) 5 (2) 14 (4)

Six respondents did not identify their country. Responses reported as number (%), percentage rounded to the nearest whole number. LMIC lower middle-income country, UMIC upper middle-income country, HIC high-income country, GA gestational age, MARSI medical adhesive-related skin injury, CONS coagulase-negative Staphylococcal. aMultiple responses allowed; bother solutions were alcohol, chlorine, chlorhexidine/alcohol and benzalkonium, sodium chloride, octenidine and hypochlorite; cother practices such as use of only sterile water, povidone-iodine, weak non-alcoholic solution, octenidine with sterile water and wiping off the cleansing solution with sterile water; dvisual inspection, homegrown local tool, neonatal skin injury and pressure injury risk assessment, Swiss neonatal skin score, Norton pressure sore risk; eother topical cord application practices included application of varying strengths of chlorhexidine or alcohol-based solutions, normal saline, calendula tincture, hydrogen peroxide, iodine-based solutions, octinidine solution, methylated spirits, and use of soap and water; fbaby oil, benzalkonium, ceramide base, cold cream, dimethacone, eucerin, silicone ointment, oil with vitamin E; gadhesive paper or plaster, band aid, brown tape, cotton or cloth tape, polyacrylate tape, silk tape; hcoconut oil, water, soap and water, emollient, saline, octenidine dihydrochloride and 2-phenoxyethanol; ikeep adhesive tapes for 24 hours, olive oil moistened cotton wool, avoid band aids, loosen edges of tape with adhesive remover and carefully peel back dressing until it is removed followed by clean site with saline wipe